News>
Picard Medical FY26 H1 net loss widens 8% to $13.28 million; revenue rises 50% to $4.1 million
- Picard Medical posted a net loss of $5.66 million for the three months ended June 30, 2026, narrowing from $6.72 million.
- Revenue rose 39% to $2.95 million, driven by an $0.8 million increase in U.S. sales.
- Operating loss widened 31% to $4.63 million as operating expenses climbed 55% to $5.25 million.
- Research and development costs increased 85% to $1.37 million on higher activity and phase scheduling in new product research.
- Emperor TAH development advanced with acute in vivo implant studies, followed by a first public platform architecture presentation at IEEE EMBC 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Picard Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-028565), on August 19, 2026, and is solely responsible for the information contained therein.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Trade now！
You may also like
Crypto prices
More
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now